Market research
SPL.AU Starpharma Holdings Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 348M
- P/E ratio
- Not available
- Analyst target
- 1.25
- Dividend yield
- Not available
- Beta
- 0.77
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000SPL0
- Market cap
- 348M
- P/E ratio
- Not available
- Analyst target
- 1.25
- Dividend yield
- Not available
- Beta
- 0.77
About
About Starpharma Holdings Limited
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom; and DEP HER2 radiodiagnostic. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SPL.AU discussion.
5 years, 5 months ago
Starpharma Holdings Limited is currently in a long term downtrend where the price is trading 17.2% below its 200 day moving average.
From a valuation standpoint, the stock is 163.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 678.2.
Starpharma Holdings Limited's total revenue sank by 77.1% to $1M since the same quarter in the previous year.
Its net income has dropped by 77.9% to $-10M since the same quarter in the previous year.
Finally, its free cash flow fell by 3.3% to $-3M since the same quarter in the previous year.
Based on the above factors, Starpharma Holdings Limited gets an overall score of 0/5.